Drug Guide

Generic Name

Polyethylene Glycol 3350

Brand Names Miralax, Glycolax

Classification

Therapeutic: Laxative

Pharmacological: Osmotic laxative

FDA Approved Indications

  • Occasional constipation

Mechanism of Action

Polyethylene glycol 3350 works by retaining water in the stool, resulting in softer stools and more frequent bowel movements.

Dosage and Administration

Adult: 17 grams (1 heaping tablespoon) dissolved in 4 to 8 ounces of fluid once daily as needed.

Pediatric: Not approved for use in children under 17 years old without medical supervision.

Geriatric: Use with caution; no specific dose adjustments, but monitor for dehydration or electrolyte imbalance.

Renal Impairment: Use cautiously; monitor electrolytes.

Hepatic Impairment: No specific dose adjustment required.

Pharmacokinetics

Absorption: Minimal; the drug acts locally in the gut.

Distribution: Not significantly absorbed systemically.

Metabolism: Not metabolized, remains unchanged.

Excretion: Excreted largely unchanged in feces.

Half Life: Not applicable, as it acts locally.

Contraindications

  • Intestinal obstruction
  • Gastrointestinal perforation or obstruction
  • Severe inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)

Precautions

  • Use with caution in patients with difficulty swallowing, dehydration, or electrolyte imbalances. Prolonged use may lead to dependence.

Adverse Reactions - Common

  • Bloating (Rare)
  • Abdominal cramps (Rare)
  • Nausea (Rare)

Adverse Reactions - Serious

  • Electrolyte imbalance (e.g., hyponatremia, hypokalemia) (Infrequent)
  • Severe allergic reactions (Rare)

Drug-Drug Interactions

  • Sodium bicarbonate, other osmotic laxatives, or medications affecting electrolyte balance.

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor bowel movements, hydration status, electrolyte levels.

Diagnoses:

  • Constipation related to decreased gut motility or diet.

Implementation: Administer as prescribed; dissolve the powder completely in fluid.

Evaluation: Assess for regular bowel movements, absence of bloating, or discomfort.

Patient/Family Teaching

  • Take as directed, dissolved in liquid.
  • Avoid excessive use to prevent dependence.
  • Report severe diarrhea, abdominal pain, or signs of electrolyte imbalance.

Special Considerations

Black Box Warnings:

  • None

Genetic Factors: None specified.

Lab Test Interference: May cause alterations in stool tests due to increased water content.

Overdose Management

Signs/Symptoms: Severe diarrhea, electrolyte imbalance, dehydration.

Treatment: Discontinuation of medication, correction of electrolytes, and supportive care.

Storage and Handling

Storage: Store at room temperature, 20-25°C (68-77°F).

Stability: Stable under recommended storage conditions.

This guide is for educational purposes only and is not intended for clinical use.